Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
Clinical trial NCT05795296 · UNKNOWN
Trial details
- NCT number
- NCT05795296
- Sponsor
- RenJi Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2024-08-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.